Q2 2020 PCI Biotech Holding ASA Earnings Call Transcript
Good morning, and welcome to PCI Biotech Second Quarter First Half 2020 Presentation Webcast here from the Oslo Cancer Cluster Innovation Park. My name is Per Walday. I'm the CEO of PCI Biotech, and I have with me also Ronny Skuggedal who is the CFO of PCI Biotech.
We will start by going through the background, the technology of the company, the company at a glance, then moving into the highlights of the first half of the year. And after that take a deeper look into the 3 different programs and the outlook. And then we will open up for questions through this webcast platform that can be submitted at the end of the presentation.
So with this, let's move over to the PCI Biotech at a glance, what are we. So PCI Biotech is a company built on a platform technology called photochemical internalization, that's PCI. What we do is that we enable intracellular delivery of medicines. We have -- this is a very broad platform that can be used for a number of different applications, but we are focusing primarily on cancer, and we are doing this through 3
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |